Janet Owens‐Grillo

Sumitomo Dainippon Pharma (United States) — United States

Medicine · Health Sciences

13h-index1.6kcitations35works2.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Urinary Bladder and Prostate Research(11), Heat shock proteins research(10), Liver Diseases and Immunity(8), Drug Transport and Resistance Mechanisms(7), Pediatric Hepatobiliary Diseases and Treatments(6)

Publications35 total

Safety and Efficacy of Vibegron in Men With Overactive Bladder Symptoms on Pharmacotherapy for Benign Prostatic Hyperplasia: Results From the 28-Week Open-Label COURAGE Extension Trial Completing the 52-Week Phase 3 Evaluation
JU Open Plus·2026· 2 citedOpen Access
Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial
Neurourology and Urodynamics·2025Open Access
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial
Urology·2025Open Access
MP11-15 THE PHASE 3 OPEN-LABEL COURAGE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF VIBEGRON IN MEN WITH OVERACTIVE BLADDER SYMPTOMS ON PHARMACOTHERAPY FOR BENIGN PROSTATIC HYPERPLASIA
The Journal of Urology·2025
Plain Language Summary of Publication: What is the effect of the medicine vibegron in the treatment of overactive bladder in patients with and without bladder leakage?
Therapeutic Advances in Urology·2025Open Access
Reply: Letter: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 COURAGE Trial
The Journal of Urology·2024Open Access
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
The Journal of Urology·2024· 19 citedOpen Access
P2-12 EFFICACY AND SAFETY OF VIBEGRON IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND SYMPTOMS OF OVERACTIVE BLADDER: RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED COURAGE TRIAL
The Journal of Urology·2024
PD54-12 EFFECT OF VIBEGRON ON QUALITY OF LIFE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND SYMPTOMS OF OVERACTIVE BLADDER: PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 RANDOMIZED CONTROLLED COURAGE TRIAL
The Journal of Urology·2024
Plain Language Summary of Publication: Does crushing vibegron 75 mg tablet affect its safety or the amount of vibegron in the body over time in healthy adults?
Therapeutic Advances in Urology·2024Open Access
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
Journal of Comparative Effectiveness Research·2023Open Access
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study
Journal of Comparative Effectiveness Research·2023Open Access
A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People with Overactive Bladder
Future Cardiology·2023· 3 citedOpen Access
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
Liver International·2019· 155 cited
Durable Response in the Markers of Cholestasis Through 36 Months of Open-Label Extension with Obeticholic Acid in Austrian and German Patients with Primary Biliary Cholangitis
Zeitschrift für Gastroenterologie·2018
Mo1455 - Disease Severity, Obeticholic Acid Disposition and dose Selection with Biliary Atresia
Gastroenterology·2018
Disease severity, obeticholic acid disposition and dose selection in patients with biliary atresia
Journal of Hepatology·2018
Durable response in the markers of cholestasis through 36 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis
Digestive and Liver Disease·2018
A200 AN INTEGRATED ANALYSIS OF EFFICACY OF OBETICHOLIC ACID IN CANADIAN PATIENTS
Journal of the Canadian Association of Gastroenterology·2018Open Access
Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Extension with Obeticholic Acid in Austrian and German Patients with Primary Biliary Cholangitis
Zeitschrift für Gastroenterologie·2017
page 1 of 2Next →

Frequent Co-authors

David Staskin(11), William B. Pratt(10), Leigh MacConell(10), Elizabeth Thomas(7), Salim Mujais(6), Louis F. Stancato(4), Kevin A. Hutchison(4), Martin R. Deibel(4), Eric S. Rovner(4), Elizabeth Smoot Malecha(4), Kai Hoffmann(3), Anthony W. Yem(3), Michael J. Czar(3), Eric Rovner(3), Kevin Cline(3), Steven G Gregg(3), Kenneth M. Peters(3), Jeffrey Frankel(3), Susann Varano(3), Adam M. Silverstein(2)